151 related articles for article (PubMed ID: 15292391)
1. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Winquist E; Berry S
J Natl Cancer Inst; 2004 Aug; 96(15):1183; author reply 1183-1184. PubMed ID: 15292391
[No Abstract] [Full Text] [Related]
2. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Tu SM; Lin SH; Logothetis C
J Natl Cancer Inst; 2003 Aug; 95(15):1174-5; author reply 1175. PubMed ID: 12902452
[No Abstract] [Full Text] [Related]
3. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
4. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
[No Abstract] [Full Text] [Related]
5. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Atkins CD
J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591994
[No Abstract] [Full Text] [Related]
6. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Rosenthal M
J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591992
[No Abstract] [Full Text] [Related]
7. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Parker CC
J Natl Cancer Inst; 2004 Oct; 96(19):1480; author reply 1480-1. PubMed ID: 15467039
[No Abstract] [Full Text] [Related]
8. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Grenader T; Shavit L; Uziely B; Peretz T
J Natl Cancer Inst; 2005 Feb; 97(3):235-6. PubMed ID: 15687369
[No Abstract] [Full Text] [Related]
9. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Bankhead C
J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
[No Abstract] [Full Text] [Related]
10. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Zheng M;
J Natl Cancer Inst; 2004 Jun; 96(11):879-82. PubMed ID: 15173273
[TBL] [Abstract][Full Text] [Related]
11. The role of bisphosphonates in hormone-refractory prostate cancer.
Saad F; Karakiewicz P; Perrotte P
World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
[TBL] [Abstract][Full Text] [Related]
12. The use of bisphosphonates in prostate cancer.
Khan MA
BJU Int; 2003 Jul; 92(1):152. PubMed ID: 12823405
[No Abstract] [Full Text] [Related]
13. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Tanvetyanon T
J Natl Cancer Inst; 2005 Jan; 97(1):70; author reply 70-1. PubMed ID: 15632382
[No Abstract] [Full Text] [Related]
14. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates in prostate cancer: where are we and where should we go?
Saad F
J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
[No Abstract] [Full Text] [Related]
16. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
17. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Gulley JL; Wu S; Arlen PM; Dahut WL
Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in the management of metastatic prostate cancer.
Heidenreich A
Oncology; 2003; 65 Suppl 1():5-11. PubMed ID: 12949427
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
